Sleep Apnea and the Root Cause Conversation
The data is now a year old, but it has not been absorbed. In June 2024, the New England Journal of Medicine published the SURMOUNT-OSA trial results: tirzepatide, the GLP-1/GIP drug sold as Mounjaro and Zepbound, reduced sleep apnea severity by roughly 50% in adults with obesity. The 52-week, placebo-controlled study showed reductions in the […]